Sofosbuvir + peginterferon/ribavirin demonstrates virologic response rates in G3 hep C patients

Results from the ground-breaking new BOSON study

2015-04-25

(Press-News.org) April 25, 2015, Vienna, Austria: Results presented today at The International Liver Congress™ 2015 demonstrate that hepatitis C (HCV)-infected genotype-3 (GT-3) patients, with and without cirrhosis, receiving 24 weeks of sofosbuvir (SOF) in combination with ribavirin (RBV) and peginterferon (PEG) achieved the highest sustained virologic response rates at 12 weeks (SVR12), observed in a Phase 3 study, to date.

Among GT-3 patients, SVR12 rates were highest in those receiving SOF+PEG/RBV for 12 weeks (93%) as compared to SOF+RBV for 24 (84%, p = 0.008) or 16 weeks (71%, p END

ELSE PRESS RELEASES FROM THIS DATE:

Alcohol use disorders - stronger predictor of mortality than chronic hepatitis C virus infection

2015-04-25

April 25, 2015, Vienna, Austria: Results presented today at The International Liver Congress™ 2015, show that alcohol use disorders (AUD) have a serious, negative prognostic outcome with higher mortality risks in the general population and patients with hepatitis C virus (HCV) infection in particular. The study found that chronic HCV infection has a limited impact on mortality, unless the patient also has other severe comorbidities, such as HIV infection, cancer or chronic kidney disease. In contrast, those with AUDs are at significant risk of death with a higher ...

Sofosbuvir/daclatasvir combination effective treatment for difficult-to-treat hep C patients

2015-04-25

April 25, 2015, Vienna, Austria: Results presented today at The International Liver Congress™ 2015 show that the sofosbuvir (SOF)/daclatasvir (DCV) treatment combination is effective amongst hepatitis C virus (HCV) genotype-1 mono-infected patients. These results are significant because whilst other combinations have been widely reported on, there have been few data until now regarding the use of SOF/DCV combination in real world situations. Overall, the sustained virologic response rate at 4 weeks (SVR4) for SOF/DCV was 81.6% after 12 weeks of treatment and 93.9% ...

DCV, SOF & RBV comb. effective/tolerated in HCV with adv, cirrhosis / post-transplant recurrence

2015-04-25

April 25, 2015, Vienna , Austria: Phase 3 results presented today at The International Liver Congress™ 2015 show that a combination of daclatasvir (DCV), sofosbuvir (SOF) and ribavirin (RBV) for 12 weeks was effective and well tolerated amongst patients with hepatitis C virus (HCV) infection with advanced cirrhosis and post-transplant recurrence. Sustained virologic response rates at 12 weeks (SVR12) were >90% in patients with Child-Pugh class A or B cirrhosis but lower in Child-Pugh class C. SVR12 was achieved by 94% of liver transplant recipients with HCV recurrence. ALLY-1 ...

Drinking just 1 or 2 alcoholic drinks a day linked to liver disease

2015-04-25

April 25, 2015, Vienna, Austria: According to the World Health Organization, excessive alcohol drinking is the most common cause of cirrhosis worldwide. A new worldwide study presented at The International Liver CongressTM 2015 has shown the significant influence of daily drinking on this disease burden. New data shows that the cirrhosis burden caused by alcohol increased by 11.13% when moving from the moderate to heavy daily drinking (up to one drink/day for women; two drinks/day for men) classification (p END ...

Prelim. safety findings: IFN-free DAA comb. with dasabuvir in chronic HCV patients

2015-04-25

April 25, 2015, Vienna, Austria: Preliminary data from an ongoing study revealed today at The International Liver Congress™ 2015 suggest that a combination of three direct-acting antivirals (DAAs) plus dasabuvir is well tolerated in patients with severe renal impairment or end-stage renal disease when used either with or without ribavirin. In addition, the combination led to rapid hepatitis C viral load suppression with no virological failures seen in the preliminary data from the ongoing open-label study. In the study, treatment naïve non-cirrhotic adults ...

Researchers highlight need for better evidence to guide EU efforts to increase hep B+C testing

2015-04-25

April 25, 2015, Vienna, Austria: The apparent dearth of research on hepatitis B and C testing in many European countries could be hampering efforts to identify infected individuals, according to results from a comprehensive review of 136 studies presented today at The International Liver CongressTM 2015. The systematic review concluded that the current evidence base on hepatitis B and C testing appears to be lacking in many European countries. At present it is informed primarily by published articles and conference abstracts from just 6 out of 53 member countries of ...

Use of pocket-sized ultrasound device reduces need for further testing in clinical settings

2015-04-25

April 25, 2015, Vienna, Austria: Results from a study presented today at The International Liver Congress™ 2015 demonstrate that the use of a pocket-sized ultrasound device (PUD) helps to reduce the need for further testing in both the inpatient and outpatient setting. The study evaluated the effectiveness of the PUD when testing for the following conditions: biliary-duct dilation, gallstones, ascites, splenomegaly, pleural effusion, pericardial effusion, urinary retention, urinary stones, abdominal mass and aortic aneurysm. PUDs offer a comparable performance ...

Hepatitis C screening essential to help catch patients with advanced liver fibrosis

2015-04-25

April 25, 2015, Vienna, Austria: Study results presented today at The International Liver Congress™ 2015 show that the occurrence of advanced liver fibrosis is similar for patients infected with the hepatitis C virus (HCV), whether or not they have been diagnosed. Most individuals with HCV remain asymptomatic, which makes the diagnosis difficult. The study authors used the hypothesis that individuals whose HCV is not diagnosed are less likely to have advanced fibrosis than those who have been diagnosed. They then compared liver fibrosis between respondents of the ...

Combined brachytherapy techniques should be 'benchmark' for cervical cancer treatment

2015-04-25

Barcelona, Spain: The first large international study to investigate the late side-effects of a combination of two forms of brachytherapy to treat cervical cancer has shown that the technique successfully delivers higher radiation doses to the tumour without an increase in treatment-related problems afterwards. Brachytherapy is a type of internal radiotherapy that involves putting a radioactive source close to, or in the tumour. It is often performed after a CT or MRI scan has pinpointed the exact position of the cancer, so that the radiation treatment can be targeted ...

Mental disorders don't predict future violence

2015-04-25

Depression is not linked to violence among males Some delinquent youth with current psychiatric illness may be violent Providing treatment could reduce violence CHICAGO --- Most psychiatric disorders - including depression -- do not predict future violent behavior, according to new Northwestern Medicine longitudinal study of delinquent youth. The only exception is substance abuse and dependence. "Our findings are relevant to the recent tragic plane crash in the French Alps. Our findings show that no one could have predicted that the pilot - who apparently ...

Researchers from NUS Medicine and the Institute of Mental Health detect early brain changes linked to future psychosis development

From novel therapies to first-in-human trials, City of Hope advances blood cancer care at the American Society of Hematology (ASH) annual conference

Research aims to strengthen the security of in-person voting machines

New study exposes hidden Alzheimer’s 'hot spots' in rural Maryland and what they reveal about America’s growing healthcare divide

[Press-News.org] Sofosbuvir + peginterferon/ribavirin demonstrates virologic response rates in G3 hep C patients
Results from the ground-breaking new BOSON study

Sofosbuvir + peginterferon/ribavirin demonstrates virologic response rates in G3 hep C patients

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: